Co-Authors
This is a "connection" page, showing publications co-authored by KAREN H LU and ANIL K SOOD.
Connection Strength
1.380
-
Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. 2021 07; 162(1):65-71.
Score: 0.204
-
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecol Oncol. 2021 03; 160(3):777-785.
Score: 0.201
-
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep. 2020 04 14; 31(2):107502.
Score: 0.190
-
Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Obstet Gynecol. 2018 09; 132(3):545-554.
Score: 0.170
-
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis. Med. 2024 Mar 07.
Score: 0.062
-
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. 2024 04 01; 130(7):1061-1071.
Score: 0.061
-
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.
Score: 0.052
-
Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2021 06; 161(3):660-667.
Score: 0.051
-
Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 04; 161(1):56-62.
Score: 0.050
-
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice. Gynecol Oncol. 2018 11; 151(2):374-380.
Score: 0.043
-
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
Score: 0.036
-
Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review. Int J Gynecol Cancer. 2016 May; 26(4):801-6.
Score: 0.036
-
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79.
Score: 0.035
-
Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015 Jun; 137(3):553-8.
Score: 0.034
-
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. J Natl Cancer Inst. 2014 Sep; 106(9).
Score: 0.032
-
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94.
Score: 0.027
-
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009 Jul; 114(1):48-52.
Score: 0.022
-
Supracervical hysterectomy in patients with advanced epithelial ovarian cancer. Obstet Gynecol. 2007 Mar; 109(3):641-6.
Score: 0.019
-
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther. 2006 Sep; 5(9):1136-41.
Score: 0.019
-
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006 Aug; 108(2):361-8.
Score: 0.018
-
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005 Nov 15; 65(22):10602-12.
Score: 0.018